Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Change in Accured Expenses (2016 - 2026)

Protara Therapeutics' Change in Accured Expenses history spans 14 years, with the latest figure at -$2.6 million for Q1 2026.

  • Quarterly Change in Accured Expenses fell 39.14% to -$2.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $89000.0 through Mar 2026, up 888.89% year-over-year, with the annual reading at $821000.0 for FY2025, 69.32% down from the prior year.
  • Change in Accured Expenses came in at -$2.6 million for Q1 2026, down from $2.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q4 2025 to a low of -$2.6 million in Q1 2026.
  • The 5-year median for Change in Accured Expenses is $140000.0 (2024), against an average of -$55117.6.
  • The largest YoY upside for Change in Accured Expenses was 1360.0% in 2025 against a maximum downside of 334.63% in 2025.
  • Protara Therapeutics' Change in Accured Expenses stood at -$1.2 million in 2022, then soared by 51.93% to -$573000.0 in 2023, then surged by 124.43% to $140000.0 in 2024, then soared by 1360.0% to $2.0 million in 2025, then crashed by 227.3% to -$2.6 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Change in Accured Expenses are -$2.6 million (Q1 2026), $2.0 million (Q4 2025), and $922000.0 (Q3 2025).